Structure Therapeutics (GPCR) Competitors $20.44 -0.07 (-0.34%) Closing price 04:00 PM EasternExtended Trading$20.74 +0.31 (+1.49%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GPCR vs. AXSM, AKRO, PCVX, ADMA, PTCT, RYTM, CYTK, KRYS, ZLAB, and ACADShould you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), Krystal Biotech (KRYS), Zai Lab (ZLAB), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Structure Therapeutics vs. Its Competitors Axsome Therapeutics Akero Therapeutics Vaxcyte ADMA Biologics PTC Therapeutics Rhythm Pharmaceuticals Cytokinetics Krystal Biotech Zai Lab ACADIA Pharmaceuticals Structure Therapeutics (NASDAQ:GPCR) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations. Which has more risk and volatility, GPCR or AXSM? Structure Therapeutics has a beta of -1.87, indicating that its share price is 287% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Do analysts prefer GPCR or AXSM? Structure Therapeutics currently has a consensus target price of $76.17, suggesting a potential upside of 272.64%. Axsome Therapeutics has a consensus target price of $172.33, suggesting a potential upside of 65.85%. Given Structure Therapeutics' higher probable upside, equities analysts clearly believe Structure Therapeutics is more favorable than Axsome Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 3.06 Which has higher valuation and earnings, GPCR or AXSM? Structure Therapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$122.53M-$0.87-23.49Axsome Therapeutics$385.69M13.27-$287.22M-$5.77-18.01 Is GPCR or AXSM more profitable? Structure Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -64.39%. Structure Therapeutics' return on equity of -16.35% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -16.35% -15.71% Axsome Therapeutics -64.39%-272.80%-36.69% Do insiders and institutionals hold more shares of GPCR or AXSM? 91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 9.4% of Structure Therapeutics shares are held by insiders. Comparatively, 22.3% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to GPCR or AXSM? In the previous week, Axsome Therapeutics had 4 more articles in the media than Structure Therapeutics. MarketBeat recorded 5 mentions for Axsome Therapeutics and 1 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.98 beat Axsome Therapeutics' score of 0.80 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryStructure Therapeutics and Axsome Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GPCR vs. The Competition Export to ExcelMetricStructure TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.18B$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-23.4921.3126.1719.90Price / SalesN/A278.47414.67113.66Price / CashN/A41.4736.1356.90Price / Book1.357.518.055.38Net Income-$122.53M-$55.05M$3.15B$248.50M7 Day Performance-6.20%2.45%1.85%2.97%1 Month Performance-6.20%7.33%4.81%6.02%1 Year Performance-47.22%5.38%34.86%20.39% Structure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GPCRStructure Therapeutics2.7017 of 5 stars$20.44-0.3%$76.17+272.6%-48.7%$1.18BN/A-23.49136AXSMAxsome Therapeutics4.6769 of 5 stars$101.65+1.0%$172.33+69.5%+27.1%$4.96B$385.69M-17.62380Analyst RevisionAKROAkero Therapeutics3.6224 of 5 stars$54.03-0.3%$82.50+52.7%+122.0%$4.32BN/A-27.7130PCVXVaxcyte1.7866 of 5 stars$33.25+1.2%$136.50+310.5%-57.2%$4.24BN/A-8.33160News CoveragePositive NewsADMAADMA Biologics4.0975 of 5 stars$17.87+0.7%$27.67+54.8%+54.8%$4.24B$426.45M21.02530PTCTPTC Therapeutics4.3298 of 5 stars$49.60-1.2%$65.00+31.0%+55.9%$3.98B$806.78M7.621,410Analyst RevisionRYTMRhythm Pharmaceuticals3.7939 of 5 stars$62.13+0.2%$76.62+23.3%+53.4%$3.94B$130.13M-22.11140CYTKCytokinetics4.2861 of 5 stars$32.64+0.6%$70.92+117.3%-38.5%$3.87B$19.22M-6.17250Positive NewsKRYSKrystal Biotech4.6224 of 5 stars$137.92+4.1%$211.13+53.1%-23.7%$3.83B$290.52M33.15210Analyst RevisionHigh Trading VolumeZLABZai Lab3.3948 of 5 stars$36.01+4.2%$47.37+31.5%+103.4%$3.81B$398.99M-14.461,869Positive NewsAnalyst ForecastInsider TradeAnalyst RevisionGap UpACADACADIA Pharmaceuticals4.6939 of 5 stars$22.48-1.0%$27.64+23.0%+33.2%$3.80B$957.80M16.41510 Related Companies and Tools Related Companies Axsome Therapeutics Alternatives Akero Therapeutics Alternatives Vaxcyte Alternatives ADMA Biologics Alternatives PTC Therapeutics Alternatives Rhythm Pharmaceuticals Alternatives Cytokinetics Alternatives Krystal Biotech Alternatives Zai Lab Alternatives ACADIA Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GPCR) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GPCR Stock Alerts